Recently, the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older.
Verywell Health on MSN
Don’t Combine These COPD Medicines
Beta-2 adrenergic agonists (also known as beta-agonists) are a mainstay treatment for COPD. There are short-acting versions used as rescue inhalers and long-acting versions that are used to control ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback